跳至主要内容
临床试验/NCT01409304
NCT01409304已完成2 期

Effectiveness of Deep Transcranial Magnetic Stimulation for Treating Major Depression: a Pilot Study

Douglas Mental Health University Institute1 个研究点 分布在 1 个国家目标入组 18 人开始时间: 2011年10月1日最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
入组人数
18
试验地点
1
主要终点
21-item Hamilton Depression Rating Scale (HAM-D21)

研究概览

简要总结

We intend to investigate whether deep transcranial magnetic stimulation (DTMS), a novel brain stimulation technique, is effective for treating major depression. We hypothesize that 4 weeks of DTMS will be associated with significant improvements in depressive and anxious symptoms without significant side effects.

详细描述

The aim of this pilot study is to assess, naturalistically, the effectiveness of deep transcranial magnetic stimulation (DTMS) in a sample of subjects with treatment-resistant depression. To do this, enrolled depressed outpatients will be assigned to receive 4 weeks of daily DTMS and will be evaluated at baseline and during week 5. We hypothesize that treatment with DTMS will be associated with significant clinical improvements in depressive and anxious symptoms, and will be well tolerated.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 60 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Presence of a current major depressive disorder (according to the DSM-IV-TR) that has not improved after ≥ 1 but ≤ 5 adequate antidepressant trial(s) in the current episode
  • Baseline score ≥ 15 on the QIDS-C
  • Stable medication regimen (> 4 weeks)

排除标准

  • Psychotic features in the current episode
  • Lifetime history of psychotic disorders and/or bipolar I or II disorders
  • Substance or alcohol abuse/dependence in the past 6 months
  • Lifetime history of a major neurological disease (e.g., Parkinson's, stroke)
  • Uncontrolled medical disease (e.g., cardiovascular, renal)
  • Pregnancy and/or lactation
  • Presence of a specific contraindication for DTMS (e.g., personal history of epilepsy, metallic head implant)
  • Hearing loss
  • Personal history of abnormal brain MRI findings

结局指标

主要结局

21-item Hamilton Depression Rating Scale (HAM-D21)

时间窗: week 5

Response to treatment is defined as a ≥ 50% reduction in the scores of the HAM-D21. Remission is defined as a HAM-D21 score ≤ 9.

次要结局

  • Quick Inventory of Depressive Symptomatology - Self-Report (QIDS-SR)(week 5)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

MARCELO T. BERLIM

Director, Neuromodulation Research Clinic

Douglas Mental Health University Institute

研究点 (1)

Loading locations...

相似试验